Showing results (111-120 of 131) with videos related to

Sort By:
Pageof 14
Annals of Hematology|November 21, 2019
Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemiaGilles Salles, Emmanuel Bachy, Lukas Smolej, et al.
Physical Review Letters|March 10, 2012
Q value and half-lives for the double-β-decay nuclide 110PdD Fink, J Barea, D Beck, et al.
Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia|September 28, 2019
Profiling of biological and environmental risk factors in immunogenetic subgroups of chronic lymphocytic leukemia - Czech national studyKamila Stranska, Karla Plevova, Hana Skuhrova Francova, et al.
The Lancet. Oncology|December 8, 2018
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trialCarol Moreno, Richard Greil, Fatih Demirkan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2020
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic LeukemiaPaolo Ghia, Andrzej Pluta, Malgorzata Wach, et al.
Casopis Lekaru Ceskych|August 19, 2003
[Intraoperative enteroscopy--personal experience from 1995 to 2002]M Kopácová, J Bures, S Rejchrt, et al.
NEJM Evidence|February 6, 2024
Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and ComorbiditiesArnon P Kater, Carolyn Owen, Carol Moreno, et al.
Hematological Oncology|October 31, 2017
Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphomaPavel Klener, Eva Fronkova, David Belada, et al.
The Lancet. Oncology|November 9, 2023
Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trialCarsten U Niemann, Talha Munir, Carol Moreno, et al.
Blood Advances|August 19, 2025
Zanubrutinib in the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studiesConstantine S Tam, Mary Ann Anderson, Martin Simkovic, et al.
Pageof 14